CPL - Chalmers Publication Library
| Utbildning | Forskning | Styrkeområden | Om Chalmers | In English In English Ej inloggad.

Mucosal Vaccine Development Based on Liposome Technology

V. Bernasconi ; Karin Norling (Institutionen för fysik, Biologisk fysik (Chalmers)) ; Marta Bally (Institutionen för fysik, Biologisk fysik (Chalmers)) ; Fredrik Höök (Institutionen för fysik, Biologisk fysik (Chalmers)) ; N. Y. Lycke
Journal of Immunology Research (2314-8861). (2016)
[Artikel, refereegranskad vetenskaplig]

Immune protection against infectious diseases is most effective if located at the portal of entry of the pathogen. Hence, there is an increasing demand for vaccine formulations that can induce strong protective immunity following oral, respiratory, or genital tract administration. At present, only few mucosal vaccines are found on the market, but recent technological advancements and a better understanding of the principles that govern priming of mucosal immune responses have contributed to a more optimistic view on the future of mucosal vaccines. Compared to live attenuated vaccines, subcomponent vaccines, most often protein-based, are considered safer, more stable, and less complicated to manufacture, but they require the addition of nontoxic and clinically safe adjuvants to be effective. In addition, another limiting factor is the large antigen dose that usually is required for mucosal vaccines. Therefore, the combination ofmucosal adjuvantswith the recent progress in nanoparticle technology provides an attractive solution to these problems. In particular, the liposome technology is ideal for combining protein antigen and adjuvant into an effective mucosal vaccine. Here, we describe and discuss recent progress in nanoparticle formulations using various types of liposomes that convey strong promise for the successful development of the next generation of mucosal vaccines.

Nyckelord: influenza subunit vaccine, mediated immune-responses, intranasal, immunization, oral vaccine, cationic liposomes, antibody-responses, delivery-system, protein corona, in-vitro, immunoadjuvant activity, Immunology, haan a, 1995, vaccine, v13, p155

Denna post skapades 2017-02-15. Senast ändrad 2017-06-29.
CPL Pubid: 248155


Läs direkt!

Länk till annan sajt (kan kräva inloggning)

Institutioner (Chalmers)

Institutionen för fysik, Biologisk fysik (Chalmers)



Chalmers infrastruktur